Citi Still Expects FDA Approval For Portola Despite 90 Day Delay
After speaking to management, Citi analyst Yigal Nochomovitz expects Portola Pharmaceuticals’ AndexXa to be approved on or before the new FDA action date of May 4, 2018. The additional data, which led to the 90 day delay, pertain, at least in part, to an update on thrombotic events in ANNEXA-4 since the last cut, Nochomovitz…